12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cellceutix, Beth Israel Deaconess deal

Cellceutix and the center partnered to research Cellceutix's Kevetrin to treat melanoma and renal cell carcinoma (RCC). Kevetrin is a small molecule protein kinase B (PKB; PKBA; AKT; AKT1) inhibitor that also...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >